Početna › Kronična limfocitna leukemija › Ohio
Kliničke studije za Kronična limfocitna leukemija u državi Ohio
43 studija za Kronična limfocitna leukemija traži sudionike na lokacijama u državi Ohio.
Gradovi u državi Ohio
- Columbus28 studija
- Cincinnati14 studija
- Cleveland8 studija
- Akron5 studija
- Toledo3 studija
- Dayton3 studija
Službeni tekst studije (engleski)
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Cleveland Clinic Akron General, Akron
- OhioHealth O'Bleness Hospital, Athens
- Avon - Richard E Jacobs Health Center, Avon
- i još 16
U tijeku regrutacijaFaza 3
Od 65 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Summa Health System - Akron Campus, Akron
- Cleveland Clinic Akron General, Akron
- Summa Health System - Barberton Campus, Barberton
- i još 44
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 40 do 75 godina · Oba spola · Ažurirano 2. lis 2026. · NCT05334069A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
- Study Site 104, Columbus
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT07582432Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland
- Cleveland Clinic Foundation, Cleveland
- Ohio State University Comprehensive Cancer Center, Columbus
- i još 2
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT04269902A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
- GC2202 Study Site 105, Canton
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT05645107A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Oncology Hematology Care Clinical Trials, Llc, Cincinnati
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06943872Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 75 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07685717A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- University Hospitals, Cleveland
- Dayton Physician Network, Dayton
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06846671A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Dayton Physician Network, Dayton
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06973187A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Oncology Hematology Care Inc, Cincinnati
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07218341Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- University of Cincinnati Medical Center, Cincinnati
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 21. ruj 2026. · NCT07648264A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Cincinnati, Cincinnati
- The Cleveland Clinic Foundation, Cleveland
- The Ohio State University, Columbus
- i još 1
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07221500Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT07061951Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
- Case Comprehensive Cancer Center, University Hospitals Seidman Cancer Center, Cleveland
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT07225439A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
- Research Site, Columbus
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT06564038A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
- The James Cancer Hospital and Solove Research Institute, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT05091424Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 31. kol 2026. · NCT07734038A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- University of Cincinnatti Medical Center, Cincinnatti
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT06528301ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
- OSU Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT07342478Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
- The Ohio State University Wexner Medical Center, Columbus
U tijeku regrutacijaFaza 1/2
Od 13 do 90 godina · Oba spola · Ažurirano 6. kol 2026. · NCT06533579A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 31. srp 2026. · NCT06708897A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Cincinnati Medical Center, Cincinnati
- Cleveland Clinic, Cleveland
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 12. lip 2026. · NCT07271667Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
- Nationwide Children's Hospital, Columbus
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 1
Od 2 godina i više · Oba spola · Ažurirano 29. svi 2026. · NCT05418088Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Cincinnati Children's Hospital Medical Center, Cincinnati
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
U tijeku regrutacijaFaza 1
Od 13 godina i više · Oba spola · Ažurirano 5. svi 2026. · NCT04771572The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
- Gabrail Cancer Center Research,, Canton
U tijeku regrutacijaFaza 1/2
Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Cleveland Clinic Main Campus /ID# 271292, Cleveland
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 9. tra 2026. · NCT06428019A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876662A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 4
Od 18 godina i više · Oba spola · Ažurirano 2. ožu 2026. · NCT06876649Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 19. velj 2026. · NCT06466122Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 19. velj 2026. · NCT05336812Study of SGR-1505 in Mature B-Cell Neoplasms
- Gabrail Cancer & Research Center, Canton
- The Ohio State University - The James Cancer Hospital, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2026. · NCT05544019Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- The Ohio State University /ID# 230439, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 9. velj 2026. · NCT04895436Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. sij 2026. · NCT05417165Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
- The Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 7. sij 2026. · NCT06043674Study of Epcoritamab as a Consolidation Therapy in CLL/SLL
- University of Cincinnati, Cincinnati
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 6. sij 2026. · NCT07108998Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
- University of Cincinnati, Cincinnati
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 6. sij 2026. · NCT07014917Acalabrutinib for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Ohio State University Comprehensive Cancer Center, Columbus
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. pro 2025. · NCT06757647AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
- Taylor Cancer Research Center, Maumee
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. pro 2025. · NCT05602363A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
- University Hospitals Cleveland Medical Center, Cleveland
- The Ohio State University - The James Cancer Hospital and Solove Research Institute, Columbus
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2025. · NCT05780034Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.